Call to Action for FDA on Counterfeit Weight Loss Drugs
A coalition that includes conservatives, activists, and various organizations has urged FDA Commissioner Dr. Marty McCulley to take action against the sale of counterfeit and hazardous weight loss medications, as reported by Breitbart News.
They expressed appreciation for President Trump’s efforts to bring pharmaceutical manufacturing back to the U.S., highlighting recent agreements with major companies to domesticize medicine production. “Production figures are looking promising and should be beneficial for America’s future,” the coalition noted in a letter to FDA officials.
However, the group pointed to concerning trends, particularly the influx of counterfeit medicines from manufacturers in China, which contradict Trump’s goal of reviving American drug manufacturing.
These counterfeit products are often available “direct to consumer” without prescriptions and tend to be either “ineffective” or outright “dangerous.”
The coalition emphasized that Chinese manufacturers frequently exploit the FDA’s “green list” to sell these counterfeit drugs.
“We are particularly alarmed that Chinese manufacturers misuse the FDA’s ‘Green List’ to introduce formulated GLP-1 products into the U.S. under the pretense of regulatory compliance. By presenting themselves as green-listed suppliers, these companies can more easily import active ingredients and finished combination forms that lack FDA approval and oversight similar to U.S. manufactured drugs. This trend risks transforming safeguards intended to foster safe trade into unregulated entry points for GLP-1 compounds. This could undermine legitimate American manufacturers and severely endanger patients in the U.S.”
The coalition has posed several questions to the FDA regarding their actions to protect the integrity of American-made GLP-1 drugs and curb the counterfeit supply. Their inquiries include:
- What is the FDA’s timeline for ensuring a secure supply of genuine American-made GLP-1 drugs while eliminating harmful counterparts?
- What kinds of safeguards could the FDA implement or already plans to put in place to ensure consumer safety and public health?
- Which federal, state, and private partners will the FDA collaborate with for this initiative?
Among the coalition’s members are:
- Saulius Anuzis, President of the American Association on Aging
- J. Kenneth Blackwell, Chairman of the National Policy Council
- Morton Blackwell, Virginia Republican National Committeeman
- Tony Perkins, Family Research Council
- Sal Russo, Co-Founder of Tea Party Express
- Tom Schatz, Citizens Against Government Waste (CAGW)
- Raul López, member of the RX Border Defense Board
This outreach to the FDA follows a poll reported by Breitbart News last August, revealing that a significant 92% of Trump voters believed the FDA should enhance its efforts to protect Americans from unsafe prescription medications.
The survey, conducted by Fabrizio Ward, a prominent pollster for Trump, indicated that his supporters are increasingly concerned about the risks posed by unsafe foreign ingredients entering the U.S. through online pharmacies and compounding companies.
“This issue transcends public health; it’s a national security crisis,” stated Raul López, director of Rx Border Defense, which commissioned the poll. “Allowing foreign adversaries like China to inundate our communities with unregulated and hazardous compounded drugs and ingredients not only jeopardizes lives but also empowers domestic violence and jeopardizes U.S. security. If we desire secure borders and safe communities, we must regain control of these foreign drug channels.”
Also advocating for enhanced oversight are thirty-eight members of the National Association of Attorneys General and eighty members of Congress, including Senator Jim Banks and Senator Marsha Blackburn. They have called on the FDA, Attorney General Pam Bondi, the Department of Homeland Security, and the Federal Trade Commission to intensify scrutiny of online sellers peddling compounded GLP-1 receptor antagonists and unregulated active pharmaceutical ingredients.
“The safety of American patients is under threat from unregulated foreign pharmaceutical factories, dubious online pharmacies, and rogue compounding operations,” López concluded. “Americans are making a definitive call: we want to halt the influx of counterfeit medicines, prioritize domestic production of essential drugs, and hold wrongdoers accountable.”
